Tang HN, Wang MW, Liu XS, Jiao Y. Personalized treatment of perihilar cholangiocarcinoma based on tumor genetic and molecular characteristics. World J Gastrointest Surg 2024; 16(9): 2769-2773 [DOI: 10.4240/wjgs.v16.i9.2769]
Corresponding Author of This Article
Yan Jiao, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, General surgery center, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Sep 27, 2024; 16(9): 2769-2773 Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2769
Personalized treatment of perihilar cholangiocarcinoma based on tumor genetic and molecular characteristics
He-Nan Tang, Ming-Wei Wang, Xue-Song Liu, Yan Jiao
He-Nan Tang, Department of Outpatient, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Ming-Wei Wang, Ministry of Health Key Laboratory of Radiobiology, School of Public Health of Jilin University, Changchun 130000, Jilin Province, China
Xue-Song Liu, Department of Gastrointestinal Surgery, Changchun Central Hospital, Changchun 130000, Jilin Province, China
Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Jiao Y designed the overall concept and outline of the manuscript; Tang HN contributed to the discussion and design of the manuscript; Tang HN, Wang MW, and Liu XS contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: The authors have claimed no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jiao, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, General surgery center, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Received: March 16, 2024 Revised: June 12, 2024 Accepted: June 21, 2024 Published online: September 27, 2024 Processing time: 185 Days and 11.6 Hours
Abstract
This editorial discusses the article written by Tchilikidi et al that was published in the latest edition of the World Journal of Gastrointestinal Surgery. Genetic and molecular profiling of perihilar cholangiocarcinoma (pCCA) has identified a number of key abnormalities that drive tumor growth and spread, including pyruvate kinase M2, proline rich 11, and transcription factor 7, etc. pCCA has specific genetic and molecular features that can be used to develop personalized treatment plans. Personalized treatment approaches offer new opportunities for effectively targeting the underlying drivers of tumor growth and progression. The findings based on tumor genetic and molecular characteristics highlight the importance of developing personalized treatment strategies.
Core Tip: Genetic and molecular profiling of perihilar cholangiocarcinoma (pCCA) has identified a number of key abnormalities that drive tumor growth and spread. pCCA is still hard to treat, and individualized anticancer treatment is required, which is supposed to be according to the genetic and molecular features. The personalized treatment should be explored to improve outcomes for patients with this challenging disease.
